These results confirmed that DYNLT1 is highly expressed in breast cancer, including but not limited to TNBC subtypes, suggesting that DYNLT1 may be a new therapeutic target for multiple subtypes of breast cancer. Here, DYNLT1 is linked to breast cancer.